The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive ...

Analytical Research Center for Organic and Biological Molecules, State Key Laboratory of Drug Research, Carbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy ...

After hours: January 29 at 4:08:12 PM EST Loading Chart for MGNX ...

Conclusions The vast majority of ACPA-IgG harbour N-glycans in their variable domains. As N-linked glycosylation requires glycosylation consensus sites in the protein sequence and as these are lacking ...

Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors. HER2 ...